Rosalba Miceli
University of Milan
CancerInternal medicineRadiologySurgeryOncologyRetrospective cohort studySurvival rateChemotherapySarcomaSoft tissue sarcomaIn patientNomogramProportional hazards modelRadiation therapyColorectal cancerBreast cancerMedicineCumulative incidenceGastroenterology
Publications 292
#1Vincenzo Marasco (University of Milan)H-Index: 1
#2Cristiana CarnitiH-Index: 21
Last. Paolo Corradini (University of Milan)H-Index: 96
view all 15 authors...
Patients affected by lymphoid malignancies (LM) are frequently immune-compromised, suffering increased mortality from COVID-19. This prospective study evaluated serological and T-cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B- and T-cell lymphomas and multiple myeloma. Results were compared with those of 167 healthy subjects matched for age and sex. Overall, patient seroconversion rate was 64·6%: serological response was lower in those...
#1Sandro PasqualiH-Index: 29
#2Emanuela PalmeriniH-Index: 35
Last. Alessandro GronchiH-Index: 94
view all 31 authors...
Background null The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS. null Methods null This study analyzed data from ISG-STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology-tailored (HT) chemotherapy in adult patients with STS. The 10-year predicted ...
#1Dario Callegaro (U of T: University of Toronto)H-Index: 2
#2Francesco BarrettaH-Index: 15
Last. Piotr RutkowskiH-Index: 85
view all 20 authors...
Abstract null null Purpose null The aim of this study was to create and validate dynamic nomograms to predict overall survival (OS) and disease-free survival (DFS) at different time points during follow-up in patients who had undergone resection of primary retroperitoneal sarcoma (RPS). null null null Methods null Patients with primary RPS operated upon between 2002 and 2017 at four and six referral centres comprised the development and external validation cohorts, respectively. Landmark analysi...
#2Hanna Eriksson (Karolinska University Hospital)H-Index: 25
#2Giovanni FucàH-Index: 16
Last. Rosalba MiceliH-Index: 65
view all 11 authors...
Background:The RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated an overall survival (OS) benefit of trifluridine/ti...
BACKGROUND The efficacy of immune checkpoint inhibitors (ICIs) in patients with microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC) is unprecedented. A relevant proportion of subjects achieving durable disease control may be considered potentially 'cured', as opposed to patients experiencing primary ICI refractoriness or short-term clinical benefit. We developed and externally validated a nomogram to estimate the progression-free survival (PFS) and the time-independent even...
BACKGROUND Prognostic parameters in sentinel node (SN)-positive melanoma are important indicators to identify patients at high risk of recurrence who should be candidates for adjuvant therapy. We aimed to evaluate the presence of melanoma cells beyond the SN capsule-extranodal extension (ENE)-as a prognostic factor in patients with positive SNs. METHODS Data from 1,047 patients with melanoma and positive SNs treated from 2001 to 2020 at the Istituto Nazionale dei Tumori in Milano, Italy, were re...
#1Anna DoderoH-Index: 21
#2Anna GuidettiH-Index: 17
Last. Annalisa ChiappellaH-Index: 30
view all 23 authors...
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (Double Expressor Lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (Double/Triple-Hit Lymphomas, DH/TH). TP53 mutations are detected in 20-25% of DEL. We report the efficacy of dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in a series of 122 consecutive patients, including DEL (n=81, 66%), DEL-MYC (n=9, 7%), DEL-BCL2 (n...
Primary retroperitoneal sarcoma (RPS) may require multivisceral resection (MVR). Clinical outcome (morbidity and renal function) and quality of life (QoL) are not as well reported as the oncologic outcome. Patients with primary RPS who underwent surgery between 2014 and 2016 were prospectively enrolled in an observational longitudinal study. At baseline, then at 4 and 12 months, the study measured Clavien–Dindo morbidity, estimated glomerular filtration rate (EGFR), EORTC QLQ-C30, QLQ-CR29, DN4 ...
#1Carolyn Nessim (Ottawa Hospital Research Institute)H-Index: 5
#2Chandrajit P. Raut (Brigham and Women's Hospital)H-Index: 65
Last. Nita Ahuja (Johns Hopkins University)H-Index: 64
view all 27 authors...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.